Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS 7 Japan Drug Majors See 2.7% Revenue Fall in FY2020, COVID-19 Forces Cuts on Guidance: Jiho Tally
February 8, 2021
-
BUSINESS Health Minister Hails Domestic Production Plan for AstraZeneca Vaccine
February 8, 2021
-
BUSINESS AstraZeneca Files COVID-19 Vaccine in Japan
February 5, 2021
-
BUSINESS MSD to Launch Silgard 9 on Feb. 24, but Mass Supply in Japan Unlikely Until 2023
February 5, 2021
-
BUSINESS Gilead Mulling Japan Entry into PIII Study for Inhaled Version of Veklury
February 5, 2021
-
BUSINESS Drug Makers Moving to Discontinue Ranitidine/Nizatidine Products over Carcinogen Issue
February 4, 2021
-
REGULATORY Celgene’s Liso-Cel Up for PAFSC Review on Feb. 17, 3rd CAR-T Therapy in Japan
February 4, 2021
-
BUSINESS Eisai Neurology Chief Says Partners Continue to Stand Behind Aducanumab
February 4, 2021
-
ORGANIZATION PhRMA Prods Japan to Harness Power of RWD in Drug Development, Medical Care Evaluation
February 3, 2021
-
REGULATORY Japan Moves Up Vaccine Rollout Target to Mid-February, PAFSC Review on Feb. 12?
February 3, 2021
-
INTERVIEW Alzheimer’s Treatment at Crossroads? Top Expert on AD Research, Aducanumab and Its Implications - 1
February 2, 2021
-
BUSINESS Teijin to Acquire Fujifilm's J-TEC for Up to 21.6 Billion Yen
February 1, 2021
-
BUSINESS FDA Delays Decision for Biogen’s Aducanumab to June 7
February 1, 2021
-
REGULATORY MHLW Wants to Encourage Non-Monitoring Facilities to Report Inappropriate Drug Promotion
January 29, 2021
-
BUSINESS Kobayashi Kako Issues Yet Another Recall, Now for 12 APIs/21 Products
January 28, 2021
-
REGULATORY Kobayashi Kako Might Face 116-Day Biz Suspension over Drug Mix-Up
January 27, 2021
-
REGULATORY Kobayashi Kako Notified of Record Biz Suspension of 110-Plus Days over Drug Mix-Up
January 26, 2021
-
REGULATORY MHLW Approves Sakigake-Designated HAE Treatment, Lilly’s Migraine Med, Takeda’s Alunbrig, Ono’s Cachexia Drug, and More
January 25, 2021
-
BUSINESS Genmab Poised to Triple Japan Staff for Stand-Alone Biz, First Up Is ADC for Cervical Cancer
January 22, 2021
-
BUSINESS Moderna’s COVID-19 Shot Enters Clinical Trial in Japan: Takeda
January 21, 2021
ページ
Takeda Pharmaceutical’s overseas sales ratio has reached 90.9%, exceeding 90% for the first time though only in the first half…
In a recent conversation with James Feliciano, former president of AbbVie Japan, we delved into the intricacies of leadership in the Japanese pharmaceutical industry. Feliciano, a seasoned industry veteran, shared valuable insights into his experiences, challenges, and successes.Navigating the Abbott…
Eli Lilly’s Kisunla (donanemab) will join the Japanese reimbursement list on November 20, with a health ministry panel giving the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…